Submitted:
11 September 2025
Posted:
12 September 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
Patient Demographics
| Group | Mean Age, years (SD), [IQR] | Mean BMI | Sex, male | Sex, female |
| Flap Surgery | 73.17 (SD=8.89) [67.2-79.1] | 25.98 (SD=4.02) | 50.0% | 50.0% |
| Simple Excision | 72.72 (SD=11.89) [64.7-80.7] | 29.61 (SD=5.34) | 46.8% | 53.2% |
| Group | Flap Surgery | Direct suture | P-value |
| Medical conditions1 | 10 (71.4%) | 25 (65.8%) | 0.707 |
| Smoking Status | 0.474 | ||
| Never smoked | 4 (28.6%) | 13 (34.2%) | |
| Former smoker | 2 (14.3%) | 8 (21.1%) | |
| Current smoker | 1 (7.1%) | 2 (5.3%) | |
| Unknown | 7 (50.0%) | 14 (36.8%) | |
| Comorbidities | |||
| Hypertension | 7 (50.0%) | 17 (44.7%) | 0.477 |
| Heart Disease | 4 (28.6%) | 5 (13.2%) | 0.241 |
| Diabetes | 1 (7.1%) | 5 (13.2%) | 0.576 |
| Melanoma | 3 (21.4%) | 7 (18.4%) | 1.000 |
| Other Cancers | 4 (28.6%) | 7 (18.4%) | 0.506 |
| NMSC Type | 0.051 | ||
| BCC | 14 (100%) | 34 (89.5%) | |
| SCC | 0 (0.0%) | 4 (10.5%) | |
| Both BCC and SCC | 0 (0.0%) | 0 (0.0%) |
Tumor Size
Complications
Facial Distribution of Surgery
| FACE-Q aspect | FS raw score | FS conversion | DS raw score | DS conversion | P-value |
| SATISFACTION WITH FACIAL APPEARANCE | 30.14 | 71 | 32.13 | 78 | 0.358 |
| APPRAISAL OF SCARS | 27.86 | 71 | 30.68 | 91 | 0.011* |
| APPEARANCE-RELATED DISTRESS |
12.14 | 23 | 10.18 | 14 | 0.058 |
| CANCER WORRY | 21.14 | 42 | 15.68 | 25 | 0.005** |
| SUN PROTECTION BEHAVIOR | 15.79 | x | 13.37 | x | 0.069 |
Association Between Cancer Worry and Scar Satisfaction


Stratified Patient Satisfaction by Anatomical Location and Treatment Type
4. Discussion
Scar Perception and Satisfaction
Psychological Impact and Cancer-Related Anxiety
Clinical Implications
Limitations and Future Directions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
AI Use Disclosure
Appendix A

| Item | Recommendation (abridged) | Where in manuscript | Compliance |
| 1a | Indicate the study design in the title or abstract | Title/Abstract (states 'prospective cohort') | Yes |
| 1b | Provide an informative and balanced abstract | Abstract | Yes |
| 2 | Explain scientific background and rationale | Introduction | Yes |
| 3 | State specific objectives/prespecified hypotheses | Introduction (Objectives) | Yes |
| 4 | Present key elements of study design early in paper | Materials and Methods (Study design) | Yes |
| 5 | Describe setting, locations, and relevant dates | Materials and Methods (Setting, dates) | Yes |
| 6a | Give eligibility criteria and methods of follow-up | Materials and Methods (Participants) | Yes |
| 6b | For matched studies, give matching criteria | Not applicable (unmatched cohort) | N/A |
| 7 | Clearly define outcomes, exposures, predictors, confounders | Materials and Methods (Variables) | Yes |
| 8 | Data sources/measurement for each variable and comparability | Materials and Methods (Data sources/measurement) | Yes |
| 9 | Describe efforts to address potential sources of bias | Materials and Methods (Bias) | Yes |
| 10 | Explain how the study size was arrived at | Materials and Methods (Study size) | Yes |
| 11 | Explain handling of quantitative variables | Materials and Methods (Quantitative variables) | Yes |
| 12a | Describe all statistical methods incl. confounding control | Materials and Methods (Statistical methods) | Yes |
| 12b | Methods for subgroup/interaction analyses | Materials and Methods (Statistical methods: subgroup/interaction) | Yes |
| 12c | How missing data were addressed | Materials and Methods (Statistical methods: missing data) | Yes |
| 12d | How loss to follow-up was addressed | Materials and Methods (Follow-up/attrition) | Yes |
| 12e | Sensitivity analyses | Materials and Methods (Sensitivity analyses) | Yes |
| 13a | Report numbers at each stage (eligible, included, follow-up, analysed) | Results (Participants) | Yes |
| 13b | Give reasons for non-participation | Results (Participants); Table A1 (Reasons for non-participation) | Yes |
| 13c | Consider a flow diagram | Results (Participant flow); Flow diagram (Figure A1, if provided) | Yes |
| 14a | Give characteristics of study participants | Results (Descriptive data); Table 2, Table 3, Table 4, Table 5 | Yes |
| 14b | Indicate number with missing data for each variable | Results (Descriptive data); Table 2, Table 3, Table 4, Table 5 | Yes |
| 14c | Summarise follow-up time | Results (Participants/Follow-up) | Yes |
| 15 | Report numbers of outcome events or summary measures over time | Results (Outcome data); Table 2, Table 3, Table 4, Table 5 Figure 1, Figure 2, figure 1 | Yes |
| 16a | Give unadjusted and adjusted estimates with precision; specify confounders | Results (Main results); Table 2, Table 3, Table 4, Table 5 | Yes |
| 16b | Report category boundaries when continuous variables were categorized | Materials and Methods/Results (Variables & Main results) | Yes |
| 16c | Translate estimates of relative risk into absolute risk if relevant | Results/Discussion (Interpretation of absolute effects) | Yes |
| 17 | Report other analyses done (subgroups, interactions, sensitivity) | Results (Other analyses) | Yes |
| 18 | Summarise key results with reference to objectives | Discussion (Key results) | Yes |
| 19 | Discuss limitations and potential bias/imprecision | Discussion (Limitations) | Yes |
| 20 | Provide a cautious overall interpretation of results | Discussion (Interpretation) | Yes |
| 21 | Discuss generalisability (external validity) of results | Discussion (Generalisability) | Yes |
| 22 | Give the source of funding and the role of the funders | Back matter (Funding) | Yes |
References
- Lomas, A., Leonardi-Bee, J., & Bath-Hextall, F. (2012). A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology, 166(5), 1069-1080. [CrossRef]
- Badash, I., Shauly, O., Lui, C.G., Gould, D.J., & Patel, K.M. (2019). Nonmelanoma Facial Skin Cancer: A Review of Diagnostic Strategies, Surgical Treatment, and Reconstructive Techniques. Clinical Medicine Insights: Ear, Nose & Throat, 12, 117955061986527. [CrossRef]
- Ciuciulete, A.R., Stepan, A.E., Andreiana, B.C., & Simionescu, C.E. (2022). Non-Melanoma Skin Cancer: Statistical Associations between Clinical Parameters. Current Health Sciences Journal, 48(1), 110-115. [CrossRef]
- Wu L, Tang S, Jiang J, Li K. Construction of a predictive model for the effectiveness of plastic surgery and repair in patients with facial basal cell carcinoma. Am J Cancer Res. 2024 Dec 15;14(12):5798-5811. PMID: 39803642; PMCID: PMC11711530. [CrossRef]
- Helmy, Y., Taha, A.M., Khallaf, A.E., & Al-Sheikh, A. (2017). Survival and aesthetic outcome of local flaps used for reconstruction of face defects after excision of skin malignancies: Multi-institutional experience of 175 cases. [CrossRef]
- Cordova LZ, Hunter-Smith DJ, Rozen WM. Patient reported outcome measures (PROMs) following mastectomy with breast reconstruction or without reconstruction: a systematic review. Gland Surg. 2019 Aug;8(4):441-451. PMID: 31538070; PMCID: PMC6723012. [CrossRef]
- van der Wal MB, Tuinebreijer WE, Bloemen MC, Verhaegen PD, Middelkoop E, van Zuijlen PP. Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars. Qual Life Res. 2012 Feb;21(1):13-23. Epub 2011 May 20. PMID: 21598065; PMCID: PMC3254877. [CrossRef]
- Lee EH, Klassen AF, Cano SJ, Nehal KS, Pusic AL. FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery. Br J Dermatol. 2018 Jul;179(1):88-94. Epub 2018 May 23. PMID: 29654700; PMCID: PMC6115303. [CrossRef]
- Ottenhof, M.J., Dobbs, T.D., Veldhuizen, I., Harrison, C.J., Marges, M., Lee, E.H., Hoogbergen, M.M., van der Hulst, R.R.W.J., Pusic, A.L., & Sidey-Gibbons, C.J. (2024). FACE-Q for Measuring Patient-reported Outcomes after Facial Skin Cancer Surgery: Cross-cultural Validation. Plastic & Reconstructive Surgery - Global Open, 12(4), e5771. [CrossRef]
- Klassen, A.F., Cano, S.J., Schwitzer, J.A., Scott, A.M., & Pusic, A.L. (2015). FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation. Plastic and Reconstructive Surgery, 135(2), 375-386. [CrossRef]
- Abu-Nab Z, Grunfeld EA. Satisfaction with outcome and attitudes towards scarring among women undergoing breast reconstructive surgery. Patient Educ Couns. 2007 May;66(2):243-9. Epub 2007 Mar 6. PMID: 17337153. [CrossRef]
- Milton A, Hambleton A, Roberts A, Davenport T, Flego A, Burns J, Hickie I: Body Image Distress and Its Associations From an International Sample of Men and Women Across the Adult Life Span: Web-Based Survey Study, JMIR Form Res 2021;5(11):e25329. [CrossRef]
- Kouwenberg, C. (2021). Psychological Impact and Cost-Effectiveness of Breast Cancer Surgery. [Doctoral Thesis, Erasmus University Rotterdam]. Erasmus Universiteit Rotterdam (EUR).
- Hammermüller, C., Hinz, A., Dietz, A. et al. Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population. BMC Cancer 21, 94 (2021).
- Zebolsky AL, Patel N, Heaton CM, Park AM, Seth R, Knott PD. Patient-Reported Aesthetic and Psychosocial Outcomes After Microvascular Reconstruction for Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1035-1044. PMID: 34292310; PMCID: PMC8299365. [CrossRef]
- Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007 Sep;17(9):643-53. Epub 2007 Jun 6. PMID: 17553702. [CrossRef]
| Complication | Flap Surgery | Direct Suture | P-value |
| Infection | 1 (7.1%) | 1 (2.6%) | 0.470 |
| Cellulitis | 1 (7.1%) | 0 (0.0%) | 0.269 |
| Minor hematoma | 2 (14.3%) | 1 (2.6%) | 0.173 |
| Necrosis | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Wound dehiscence | 1 (7.1%) | 0 (0.0%) | 0.269 |
| Major complications | 3 (21.4%) | 1 (2.6%) | 0.055 |
| Anatomical_location | Direct Suturing | Flap Surgery |
| Cheeks | 14 (36.8%) | 1 (7.1%) |
| Chin | 1 (2.6%) | 0 (0.0%) |
| Forehead | 6 (15.8%) | 2 (14.3%) |
| Lips/Perioral Area | 6 (15.8%) | 0 (0.0%) |
| Nose | 3 (7.9%) | 11 (78.6%) |
| Periorbital Area | 1 (2.6%) | 0 (0.0%) |
| Temple | 7 (18.4%) | 0 (0.0%) |
| Anatomical Location | n (FS) | Median (IQR) Satisfaction (FS) | n (DS) | Median (IQR) Satisfaction (DS) | ||
| Cheek | 1 | 9.0 (9.0–9.0) | 14 | 10.0 (9.0–10.0) | ||
| Forehead | 2 | 10.0 (10.0–10.0) | 6 | 9.0 (8.5–9.5) | ||
| Nose | 11 | 8.5 (8.0–9.0) | 3 | 8.5 (8.0–8.5) | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).